Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease - Wikidata - awgldk - TriplyDB

Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease

Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease

http://www.wikidata.org/entity/Q37153759

about

Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases Implication of hepatokines in metabolic disorders and cardiovascular diseases Roles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease The FGF21-adiponectin axis in controlling energy and vascular homeostasis Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders.Roles of FGF Signals in Heart Development, Health, and Disease Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21 Irisin levels are lower in young amenorrheic athletes compared with eumenorrheic athletes and non-athletes and are associated with bone density and strength estimates Hepatokines as a Link between Obesity and Cardiovascular Diseases.Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients Serum Level of Fibroblast Growth Factor 21 Is Independently Associated with Acute Myocardial Infarction.Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes.Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes.Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice.Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases Fibroblast growth factor-21 is positively associated with atrial fibrosis in atrial fibrillation patients with rheumatic heart disease.Circulating Fibroblast Growth Factor 21 is Associated with Diastolic Dysfunction in Heart Failure Patients with Preserved Ejection Fraction.Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Contribution of serum FGF21 level to the identification of left ventricular systolic dysfunction and cardiac death.Fibroblast growth factor 21: a regulator of metabolic disease and health span.Cardiac actions of fibroblast growth factor 23.Epicardial fat, body mass index, and triglyceride are independent contributors of serum fibroblast growth factor 21 level in obese premenopausal women.Fibroblast growth factor 21 protects rat cardiomyocytes from endoplasmic reticulum stress by promoting the fibroblast growth factor receptor 1-extracellular signal‑regulated kinase 1/2 signaling pathway.Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action.Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus.Low Plasma Levels of Fibroblast Growth Factor-21 in Patients with Peripheral Artery Disease.The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis.Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study.Impact of fibroblast growth factor 21 on the secretome of human perivascular preadipocytes and adipocytes: a targeted proteomics approach.The role of FGF21 in type 1 diabetes and its complications.A high circulating FGF21 level as a prognostic marker in patients with acute myocardial infarction Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris

P2860

Q26744232-ED9F6F72-E062-47DF-AECD-DB47C1C64EBF Q26751147-742E8DBD-0C87-4C4D-B28F-D381A1F1EE54 Q26752330-38A82CF6-B8B6-4B22-B674-707809A5F7B2 Q26753369-BDDE5FEA-1985-4918-916D-AF37E271BF7C Q27686803-DCC219AA-D0AB-4EF0-A264-0FCAB8E2321A Q28072691-ABB11DC3-3BE1-4504-AEEF-CDADFE18EB76 Q28084197-4A09B851-96DA-4E07-810C-62373A7C0309 Q33754566-DE162EDA-2AAB-4E1C-BE41-0D3144369CE5 Q35126823-B3C0F3A3-D073-4FFE-B885-7CEA44FC4E74 Q35176887-36279F63-E288-4459-BA06-3064CFA4B145 Q35668795-1684B5A5-25ED-4D9C-B5DF-7D0A74EA7AC8 Q35762326-7F1C08D2-18BA-4CDD-A143-C3826F8CD95C Q35784028-6E05F3E4-BB15-4821-8E46-EE0448E011C3 Q35794417-7AAB431B-782A-4C11-A4CA-99FAC653EA69 Q36107291-38334633-BA50-4841-9BEC-FE985B723A8D Q36464699-E3BD07C2-7964-48E5-8F05-5E9BE8D23FFA Q37271698-FFE966EE-07AA-4C92-AF18-B90041214C81 Q37689828-EADD7F28-B1A4-4303-B8BC-5180BF9CA3DC Q38618204-4324A1F5-C65B-47E1-A38F-4E576B871F04 Q38755577-EC9483D7-A54F-4381-8B51-DBDECC9E107C Q38977291-36E22E1A-CBBB-49D2-A576-C627622F432D Q39113702-6A44C351-054D-4968-ACCC-85665057A87E Q41834382-AA197FFF-280E-4789-B8FA-5DFEDD06E3DB Q42359780-66189BDC-F3BA-414A-81D5-9CF3F7DAC57A Q42504526-B989B0E9-7422-41DC-B981-AD0F4B91FE6A Q42541271-DDCA1E89-4E08-4B41-8827-CBC84BCED6A0 Q47135571-BC1F4996-E4E8-43E7-A8E6-3A00AA261016 Q47547083-BDDB103C-51AC-46AE-8D65-F9E4BE9906AF Q49914044-7A208150-563F-4E0D-BE24-5B64C57A62BC Q50049416-3337D613-651C-440A-8CB7-27239C89374F Q51592405-76FD4FF6-2CEF-437D-92F9-6068AFD4CDE3 Q55513236-2EE4AAA2-B1A4-4D43-864E-341CA0BBB7E6 Q57493364-48C2678D-941D-45BF-83EB-59C366682317 Q58699532-ED74F0AA-060F-48FC-B581-3560747A14B0

P2860

Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease

http://www.wikidata.org/entity/Q37153759

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Additive relationship between ...... el and coronary artery disease

@en

Additive relationship between ...... l and coronary artery disease.

@nl

type

label

Additive relationship between ...... el and coronary artery disease

@en

Additive relationship between ...... l and coronary artery disease.

@nl

prefLabel

Additive relationship between ...... el and coronary artery disease

@en

Additive relationship between ...... l and coronary artery disease.

@nl

P1433

Q37153759-72B06020-51C0-40E7-96C7-96A92061620F

P1476

Q37153759-63738DE7-6ECB-4D36-BAF5-F111D4FC5900

P2093

Q37153759-022DD370-71FC-49F0-A2CC-DBA454CA8E73

Q37153759-07837D21-019E-4C13-9717-05DD971BD7E4

Q37153759-2C48141B-0769-4208-9871-2812EEE815EF

Q37153759-4287BD77-AF55-4E63-99D6-3DE955FC332D

Q37153759-97D8516F-3C75-40D0-B25B-8819A6F2E3CF

Q37153759-A397C5BD-3978-4D73-88E3-274A903B06DD

Q37153759-A7DEE915-975B-4989-92EF-F0895424EDEF

Q37153759-A9EB8BCC-3024-4190-A547-81465C8DBDEC

Q37153759-B3AD8A9D-A469-458A-9599-2F81668377F5

Q37153759-EFF0C795-C68F-477D-BC2F-F61E2B111173

P2860

Q37153759-00B70AFE-3591-4DC0-92D9-217376B4540E

Q37153759-038C1BEE-D77C-4629-BE0F-5F062791F923

Q37153759-186AB245-E30A-41D6-A46F-1602B761EBD4

Q37153759-1DAFD844-AC4F-4399-99E5-00B14E9C13BE

Q37153759-297EE455-F652-419A-80D2-A5D6E9857DBC

Q37153759-3ADA6806-11BB-404B-8F85-FC6EF185F6A7

Q37153759-4A351EC4-C8F0-430D-BAF1-7F5175612BFB

Q37153759-53005E33-7A8D-402B-B497-64CBB8FF29E0

Q37153759-5750A5BB-6396-40F1-95F2-B8FC33BE49E9

Q37153759-5E007A83-D484-45C9-8852-FE371F57DFDF

P2888

Q37153759-8E4BBB31-5D65-45BF-BD67-B4CA05061743

P304

Q37153759-09BFEE3D-1075-4EFE-BB0C-A67CE48A8E11

P31

Q37153759-DE64876D-A4D1-4288-B289-073E6AAF8773

P356

Q37153759-533EF5EA-C927-4EA5-AD2B-4B8829FB2B3E

P407

Q37153759-0E943D71-4F71-4CF6-8AED-6EBD88ACB800

P478

Q37153759-23C1EA2F-8D91-49AC-B218-A347AB5021BE

P577

Q37153759-78420C1B-BE0D-4485-809C-E3AD41BE1DEF

P5875

Q37153759-E6320BDB-D7D7-4760-B800-727390918317

P6179

Q37153759-BE4E0443-B7AE-42DE-ABE7-7A327F4FE012

P698

Q37153759-3A050D40-D0ED-4D2E-A52C-1840ED80312D

P932

Q37153759-8EF77276-89E3-43DF-8F23-54DC731FD3EF

P356

1475-2840-12-124

P1433

Cardiovascular Diabetology

P1476

Additive relationship between ...... el and coronary artery disease

@en

P2093

Jian Zhou

http://www.w3.org/2001/XMLSchema#string

Meifang Gao

http://www.w3.org/2001/XMLSchema#string

Mi Zhou

http://www.w3.org/2001/XMLSchema#string

Weiping Jia

http://www.w3.org/2001/XMLSchema#string

Xiaojing Ma

http://www.w3.org/2001/XMLSchema#string

Xiaoping Pan

http://www.w3.org/2001/XMLSchema#string

Yaping Hao

http://www.w3.org/2001/XMLSchema#string

Yun Shen

http://www.w3.org/2001/XMLSchema#string

Yuqian Bao

http://www.w3.org/2001/XMLSchema#string

Zhigang Lu

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a novel FGF, FGF-21, preferentially expressed in the liver

Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells

Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

Serum FGF-21 levels in type 2 diabetic patients.

Fibroblast growth factor 21 corrects obesity in mice.

Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging.

Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?

Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment.

Alanine aminotransferase/aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults.

Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus.

P2888

1475-2840-12-124

P304

124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1475-2840-12-124

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256188212

http://www.w3.org/2001/XMLSchema#string

P6179

1037766877

http://www.w3.org/2001/XMLSchema#string

P698

23981342

http://www.w3.org/2001/XMLSchema#string

P932

3766150

http://www.w3.org/2001/XMLSchema#string